Hepatocellular carcinoma and antidepressants: a nationwide population-based study

Vincent Chin-Hung Chen; Chiao-Fan Lin; Yi-Hsuan Hsieh; Hsin-Yi Liang; Kuo-You Huang; Wei-Che Chiu; Yena Lee; Roger S. McIntyre; Hsiang-Lin Chan

doi:10.18632/oncotarget.12826

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Hepatocellular carcinoma and antidepressants: a nationwide population-based study

Vincent Chin-Hung Chen _, Chiao-Fan Lin, Yi-Hsuan Hsieh, Hsin-Yi Liang, Kuo-You Huang, Wei-Che Chiu, Yena Lee, Roger S. McIntyre and Hsiang-Lin Chan

PDF | HTML | How to cite

Oncotarget. 2017; 8:30464-30470. https://doi.org/10.18632/oncotarget.12826

Metrics: PDF 2094 views | HTML 2927 views | ?

Abstract

Vincent Chin-Hung Chen1,2 , Chiao-Fan Lin2,3, Yi-Hsuan Hsieh2,3, Hsin-Yi Liang2,3, Kuo-You Huang4, Wei-Che Chiu5,6,*, Yena Lee7, Roger S. McIntyre7,8 and Hsiang-Lin Chan2,3

1 Department of Psychiatry, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan

2 Department of Psychiatry, Chang Gung University, Taoyuan, Taiwan

3 Department of Child Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

4 Department of Speech, Language Pathology and Audiology, Chung Shan Medical University, Taichung, Taiwan

5 Department of Psychiatry, Cathay General Hospital, Taipei, Taiwan

6 School of Medicine, Fu Jen Catholic University, Taipei, Taiwan

7 Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, USA

8 Department of Psychiatry, University of Toronto, Toronto, ON, USA

* Dr. Wei-Che Chiu contributes equally to Dr. Hsiang-Lin Chan

Correspondence to:

Hsiang-Lin Chan, email:

Keywords: hepatocellular carcinoma, antidepressants, Taiwan national insurance

Received: July 18, 2016 Accepted: October 19, 2016 Published: October 23, 2016

Abstract

Hepatocellular carcinoma (HCC) is highly prevalent in Asia. Antidepressants have been associated with increase in hepatocellular carcinoma. This is the first Asian population-based study to evaluate the association between antidepressant use and risk of HCC. Based on Taiwan’s National Health Insurance Research Database, we conducted a nationwide population-based study. A total of 49,998 cases with HCC were identified and paired with 244,236 randomly selected controls. The data was analyzed via the conditional logistic regression model adjusting for several confounding factors. Use of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) was associated with lower risk for HCC. No apparent association was found between use of other classes of antidepressants and HCC, including monoamine oxidase inhibitors (MAOIs), serotonin norepinephrine reuptake inhibitors (SNRIs), trazodone, mirtazapine and bupropion. The findings of a protective effect of TCAs and SSRIs for HCC should be interpreted with caution and warrants further research.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12826

Publication Alerts

Clinical Research Papers:

Hepatocellular carcinoma and antidepressants: a nationwide population-based study

Abstract